ArticleBiological psychiatry2015
DNA modification study of major depressive disorder: beyond locus-by-locus comparisons.
Article in Biological psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Epigenome-wide association study meta-analysis of wellbeing.Clinical epigenetics · 2026Pooled it
- Pooled it
- An epigenome-wide association study of early-onset major depression in monozygotic twins.Translational psychiatry · 2020Pooled it
- What do DNA methylation studies tell us about depression? A systematic review.Translational psychiatry · 2019Pooled it
- Decoding the Methylome: Insights into the Epigenetic Regulation of Polycystic Ovarian Syndrome through Mitochondrial DNA Methylation.Current genomics · 2025Review
- Psychiatric disorders and comorbidity in women with Turner Syndrome: a retrospective national cohort study.Translational psychiatry · 2024Article
- Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential.Signal transduction and targeted therapy · 2023Review
- Review
- Towards AI-driven longevity research: An overview.Frontiers in aging · 2023Review
- DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?Current neuropharmacology · 2022Review
- Modeling heritability of temperamental differences, stress reactivity, and risk for anxiety and depression: Relevance to research domain criteria (RDoC).The European journal of neuroscience · 2022Review
- Methylome-wide association study of early life stressors and adult mental health.Human molecular genetics · 2022Article
- Origins of human disease: the chrono-epigenetic perspective.Nature reviews. Genetics · 2021Review
- Methylome-wide association findings for major depressive disorder overlap in blood and brain and replicate in independent brain samples.Molecular psychiatry · 2020Article
- Enhancer transcription identifiesDevelopment (Cambridge, England) · 2020Article
- Moving pharmacoepigenetics tools for depression toward clinical use.Journal of affective disorders · 2019Review
- DNA methylation in adolescents with anxiety disorder: a longitudinal study.Scientific reports · 2018Article
- Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Journal of affective disorders · 2018Review
- Epigenetic variability in conversion to psychosis: novel findings from an innovative longitudinal methylomic analysis.Translational psychiatry · 2018Article
- A Clinician's Perspective on Biomarkers.Focus (American Psychiatric Publishing) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 13 institutions in 7 countries.
Funding
Abstract
backgroundMajor depressive disorder (MDD) exhibits numerous clinical and molecular features that are consistent with putative epigenetic misregulation. Despite growing interest in epigenetic studies of psychiatric diseases, the methodologies guiding such studies have not been well defined.
methodsWe performed DNA modification analysis in white blood cells from monozygotic twins discordant for MDD, in brain prefrontal cortex, and germline (sperm) samples from affected individuals and control subjects (total N = 304) using 8.1K CpG island microarrays and fine mapping. In addition to the traditional locus-by-locus comparisons, we explored the potential of new analytical approaches in epigenomic studies.
resultsIn the microarray experiment, we detected a number of nominally significant DNA modification differences in MDD and validated selected targets using bisulfite pyrosequencing. Some MDD epigenetic changes, however, overlapped across brain, blood, and sperm more often than expected by chance. We also demonstrated that stratification for disease severity and age may increase the statistical power of epimutation detection. Finally, a series of new analytical approaches, such as DNA modification networks and machine-learning algorithms using binary and quantitative depression phenotypes, provided additional insights on the epigenetic contributions to MDD.
conclusionsMapping epigenetic differences in MDD (and other psychiatric diseases) is a complex task. However, combining traditional and innovative analytical strategies may lead to identification of disease-specific etiopathogenic epimutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.